Rigel Pharmaceuticals (RIGL) Free Cash Flow (2010 - 2026)

Rigel Pharmaceuticals' Free Cash Flow history runs 17 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 405.15% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $79.3 million (up 122.73% YoY), while the FY2025 annual figure was $75.7 million, up 140.4% from the prior year.
• Free Cash Flow for Q1 2026 stood at $2.7 million, down from $22.0 million in the prior quarter.
• The five-year high for Free Cash Flow was $30.5 million in Q2 2025, with the low at -$25.9 million in Q1 2022.
• The 5-year median for Free Cash Flow is -$893000.0 (2025), against an average of $1.8 million.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow plunged 123.52% in 2022, then surged 10011.59% in 2025.
• Rigel Pharmaceuticals' Free Cash Flow stood at -$22.8 million in 2022, then jumped by 72.56% to -$6.3 million in 2023, then surged by 331.34% to $14.5 million in 2024, then soared by 51.55% to $22.0 million in 2025, then tumbled by 87.6% to $2.7 million in 2026.
• Business Quant data shows RIGL's Free Cash Flow at $2.7 million in Q1 2026, $22.0 million in Q4 2025, and $24.0 million in Q3 2025.